UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other J ...

50 rac RIPLE CLEAN First Quarter FY 2023 Results August 4th, 2022 Prestige Consumer HEALTHCARE O ENSITIVE ULTIMATE Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, diluted EPS, EBITDA, free cash flow, and organic revenue growth; the impact of branded POS on the market share of Hydralyte; the Company's ...

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q1 2023 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Phil Terpolilli - Vice President, Investor Relations and Treasurer Ron Lombardi - Chairman, President and CEO Christine Sacco - Chief Financial Officer Conference Call Participants Chris Neamonitis - Jefferies Jon Andersen - William Blair Mitch Pinheiro - Sturdivant Erica Eiler - Oppenheimer Linda Bolton Weiser - D.A. Davidson Operator Good morning. And welcome to the Prestige Consume ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisd ...

M a y 6 t h , 2 0 2 2 Full-Year FY 22 Results & Business Attributes Review HEALTHCARE Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, diluted EPS, free cash flow, and organic revenue growth; the Company's ability to perform well in the currently evolving environment, including in light of the impact o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______ TO ______ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Inco ...

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q4 2022 Earnings Conference Call May 6, 2022 8:30 AM ET Company Participants Phil Terpolilli - VP, IR Ron Lombardi - Chairman, President and CEO Christine Sacco - CFO Conference Call Participants Rupesh Parikh - Oppenheimer Stephanie Wissink - Jefferies Jon Anderson - William Blair Linda Bolton Weiser - D.A. Davidson Anthony Lebiedzinski - Sidoti Operator Good day ladies and gentlemen, thank you for standing by. And welcome to the Prestige Consumer Healthcare, In ...

Financial Data and Key Metrics Changes - Revenues for Q3 2022 were $275 million, representing a 15% increase compared to the prior year, consistent with year-to-date trends [7][18] - EBITDA increased by approximately 11%, with EBITDA margins remaining stable in the mid-30s [20] - Diluted earnings per share for the quarter was $0.99, up 22% year-over-year, driven by higher sales and lower interest expenses [20] Business Line Data and Key Metrics Changes - North America revenues increased by about 14%, with significant organic growth in GI, ear and eye care, and cough and cold categories [18] - The international segment saw an approximate 18% increase in Q3, benefiting from strong sales of the Hydralyte brand [19] Market Data and Key Metrics Changes - The company experienced a rebound in cough and cold product sales, which had been impacted by COVID-19, contributing to incremental sales in Q3 [8][13] - E-commerce channel consumption growth continued to be double digits year-over-year, reflecting a shift in consumer purchasing behavior [21] Company Strategy and Development Direction - The company is focused on leveraging its diversified portfolio to drive long-term growth and navigate supply chain challenges [15][28] - Capital allocation priorities include continued de-levering, considering M&A opportunities, and opportunistic stock buybacks [35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the business momentum and anticipated continued growth despite potential headwinds from COVID-19 disruptions [28][30] - The company raised its full-year revenue outlook to between $1.75 billion and $1.80 billion, with an expected organic growth of about 9% [28] Other Important Information - The company generated approximately $65 million in free cash flow for Q3, up double digits from the prior year [9] - The acquisition of Akorn consumer brands is performing well and aligns with the company's expectations [10] Q&A Session Summary Question: Outlook for next year regarding growth - Management indicated optimism about growth, expecting organic growth even after record results in the current year [34] Question: Capital allocation strategy if below targeted debt-to-EBITDA ranges - Capital allocation priorities will remain consistent, focusing on de-levering, M&A opportunities, and stock buybacks [35] Question: Magnitude of inflationary pressures faced - Management noted $10 million to $15 million of inflationary pressure and indicated that pricing actions have been taken across the majority of the portfolio [36] Question: E-commerce growth and its future - E-commerce growth is expected to continue outpacing brick-and-mortar growth, with ongoing investments in this channel [42] Question: Supply chain concerns - Management expressed confidence in their diverse supplier base and did not identify any specific inputs of concern [85] Question: Innovations and share gains in products - New product launches have occurred, with notable share gains in brands like Dramamine and Clear Eyes [67] Question: Changes in consumer behavior post-COVID - Management noted a long-term trend towards increased consumer focus on health and wellness, which aligns with the company's product offerings [54]

RIPLE CLEAI 0 ULTIMATE 50 ma February 3rd, 2022 Prestige Consumer HEALTHCARE Third Quarter FY 2022 Results Safe Harbor Disclosure 2 This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, adjusted diluted EPS, and free cash flow; the Company's ability to perform well in the currently evolving environment and execute on its brand-bu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) 660 White Plains R ...